Pharmacological neutralization of the ET-1-endothelin B receptor (ETBR) signaling axis in a preclinical ovarian cancer model resulted in increased intratumoral CD8+ T cell infiltration and subsequent tumor response to an otherwise ineffective autologous cancer cell vaccine (14). This evidence concerns the gene CD8A and neoplasm.